Thomas Stankovich - 04 Aug 2023 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Issuer symbol
RSLS
Transactions as of
04 Aug 2023
Net transactions value
-$386
Form type
4
Filing time
08 Nov 2023, 16:16:25 UTC
Previous filing
19 Jul 2023
Next filing
13 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale $154 -108 -0.46% $1.43 23,276 04 Aug 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $55.38 -39 -0.17% $1.42 23,237 24 Aug 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $105 -118 -0.51% $0.8900 23,119 01 Sep 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $36.27 -39 -0.17% $0.9300 23,080 11 Oct 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $35.37 -131 -0.57% $0.2700 22,949 25 Oct 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.